Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489):

Slides:

Advertisements

Similar presentations

Crohn's disease Prof Daniel C Baumgart, MD, Prof William J Sandborn, MD The Lancet Volume 380, Issue 9853, Pages (November 2012) DOI: /S (12)

Advertisements

Maternal gestational vitamin D supplementation and offspring bone health (MAVIDOS): a multicentre, double-blind, randomised placebo-controlled trial

Volume 387, Issue 10037, Pages (June 2016)

Volume 390, Issue 10101, Pages (September 2017)

Volume 14, Issue 4, Pages (April 2013)

Volume 389, Issue 10074, Pages (March 2017)

Enhanced performance feedback and patient participation to improve hand hygiene compliance of health-care workers in the setting of established multimodal.

Volume 12, Issue 9, Pages (September 2011)

Volume 380, Issue 9846, Pages (September 2012)

Volume 383, Issue 9920, Pages (March 2014)

Volume 357, Issue 9273, Pages (June 2001)

Volume 367, Issue 9517, Pages (April 2006)

Surgery versus conservative management for recurrent and ongoing left-sided diverticulitis (DIRECT trial): an open-label, multicentre, randomised controlled.

Volume 375, Issue 9729, Pages (May 2010)

Volume 2, Issue 1, Pages e12-e19 (January 2015)

Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS Reflate TB): a multicentre, phase 2, non-comparative, open-label,

Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg- positive chronic hepatitis B virus infection: a randomised, double-blind,

Switch from TDF-based to Elvitegravir-Cobicistat-TAF-FTC Study 109

Volume 11, Issue 4, Pages (April 2012)

Volume 388, Issue 10042, Pages (July 2016)

Pulmonary effects of immediate versus deferred antiretroviral therapy in HIV-positive individuals: a nested substudy within the multicentre, international,

Volume 389, Issue 10069, Pages (February 2017)

Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg- positive chronic hepatitis B virus infection: a randomised, double-blind,

Switch from TDF to TAF GS-US Study GS-US Study

Maternal gestational vitamin D supplementation and offspring bone health (MAVIDOS): a multicentre, double-blind, randomised placebo-controlled trial

Intravenous or nebulised magnesium sulphate versus standard therapy for severe acute asthma (3Mg trial): a double-blind, randomised controlled trial

Volume 5, Issue 4, Pages (April 2006)

Volume 14, Issue 4, Pages (April 2013)

Volume 371, Issue 9611, Pages (February 2008)

Volume 387, Issue 10033, Pages (May 2016)

Volume 13, Issue 3, Pages (March 2012)

Effect of intravenous haloperidol on the duration of delirium and coma in critically ill patients (Hope-ICU): a randomised, double-blind, placebo-controlled.

Volume 12, Issue 9, Pages (September 2013)

Midlife contributors to socioeconomic differences in frailty during later life: a prospective cohort study Prof Eric J Brunner, PhD, Martin J Shipley,

Mannose-binding lectin deficiency and disease severity in non-cystic fibrosis bronchiectasis: a prospective study Dr James D Chalmers, MBChB, Brian J.

Volume 379, Issue 9816, Pages (February 2012)

Volume 373, Issue 9663, Pages (February 2009)

Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug classes:

Surgery versus conservative management for recurrent and ongoing left-sided diverticulitis (DIRECT trial): an open-label, multicentre, randomised controlled.

Volume 2, Issue 12, Pages (December 2015)

AQ-13, an investigational antimalarial, versus artemether plus lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria: a randomised,

Volume 9, Issue 10, Pages (October 2008)

Volume 381, Issue 9884, Pages (June 2013)

Volume 378, Issue 9801, Pages (October 2011)

Volume 387, Issue 10033, Pages (May 2016)

Resuscitation at birth and cognition at 8 years of age: a cohort study

Volume 379, Issue 9821, Pages (March 2012)

Volume 383, Issue 9920, Pages (March 2014)

Volume 15, Issue 1, Pages (January 2014)

Volume 3, Issue 9, Pages e421-e430 (September 2016)

Volume 16, Issue 1, Pages (January 2017)

Tadalafil in patients with chronic obstructive pulmonary disease: a randomised, double- blind, parallel-group, placebo-controlled trial Dr Andrew R Goudie,

Volume 386, Issue 10011, Pages (December 2015)

Volume 12, Issue 8, Pages (August 2013)

Volume 381, Issue 9868, Pages (March 2013)

Volume 388, Issue 10056, Pages (October 2016)

Intravenous or nebulised magnesium sulphate versus standard therapy for severe acute asthma (3Mg trial): a double-blind, randomised controlled trial

Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised,

Volume 2, Issue 10, Pages e417-e426 (October 2015)

Volume 15, Issue 13, Pages (December 2014)

Primary prophylaxis of cryptococcal disease with fluconazole in HIV-positive Ugandan adults: a double-blind, randomised, placebo-controlled trial Dr.

Volume 17, Issue 8, Pages (August 2016)

Department of Error The Lancet Volume 369, Issue 9564, (March 2007)

Effect of standard dose paracetamol versus placebo as antipyretic therapy on liver injury in adult dengue infection: a multicentre randomised controlled.

Volume 393, Issue 10177, Pages (March 2019)

Volume 383, Issue 9930, Pages (May 2014)

Volume 14, Issue 7, Pages (June 2013)

Clinic attendance and disengagement of young adults with type 1 diabetes after transition of care from paediatric to adult services (TrACeD): a randomised,

Volume 371, Issue 9611, Pages (February 2008)

Comparison of INSTI vs INSTI

Presentation transcript:

Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial Joel Gallant, MD, Prof Adriano Lazzarin, MD, Anthony Mills, MD, Chloe Orkin, MD, Daniel Podzamczer, MD, Pablo Tebas, MD, Prof Pierre-Marie Girard, MD, Indira Brar, MD, Eric S Daar, MD, David Wohl, MD, Prof Jürgen Rockstroh, MD, Xuelian Wei, PhD, Joseph Custodio, PhD, Kirsten White, PhD, Dr Hal Martin, MD, Andrew Cheng, MD, Erin Quirk, MD The Lancet DOI: 10.1016/S0140-6736(17)32299-7 Copyright © 2017 Elsevier Ltd Terms and Conditions

Figure 1 Trial profile B/F/TAF=bictegravir, emtricitabine, and tenofovir alafenamide. DTG/ABC/3TC=dolutegravir, abacavir, and lamivudine. The Lancet DOI: (10.1016/S0140-6736(17)32299-7) Copyright © 2017 Elsevier Ltd Terms and Conditions

Figure 2 Proportion of participants with HIV-1 RNA less than 50 copies per mL Missing-as-excluded analysis. Error bars represent 95% CIs. B/F/TAF=bictegravir, emtricitabine, and tenofovir alafenamide. DTG/ABC/3TC=dolutegravir, abacavir, and lamivudine. The Lancet DOI: (10.1016/S0140-6736(17)32299-7) Copyright © 2017 Elsevier Ltd Terms and Conditions

Figure 3 Mean percentage change from baseline in hip and lumbar spine bone mineral density As determined by dual energy X-ray absorptiometry scan. Error bars represent 95% CIs. B/F/TAF=bictegravir, emtricitabine, and tenofovir alafenamide. DTG/ABC/3TC=dolutegravir, abacavir, and lamivudine. *B/F/TAF versus DTG/ABC/3TC at week 48 by ANOVA. The Lancet DOI: (10.1016/S0140-6736(17)32299-7) Copyright © 2017 Elsevier Ltd Terms and Conditions